Comparison of Calcium Blocking Activities of Adenosine Potentiating Compounds With Calcium Blocking Drugs in Isolated Smooth Muscle and Atria

  • Y. Nakagawa
  • M. Gudenzi
  • S. Jamal Mustafa
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 39)


It is widely recognized that calcium ions play a vital role in many cell processes and in a variety of muscle tissues (particularly in the function of cardiac tissue and vascular smooth muscle). Since Fleckenstein et al. (1) in 1969 reported the inhibition of myocardial contractility by calcium antagonists, extensive investigation of the pharmacologic properties and the therapeutic applications of these drugs have been carried out in the last decade (2–11). These drugs are also known as “calcium antagonists”, “slow- channel inhibitors”, “calcium channel blockers” or “calcium entry blockers”.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fleckenstein A, Tritthart B, Fleckenstein B, Herbst A, Grun G: Selective inhibition of myocardial contractility by competitive calcium antagonists (iproveratril, D600, prenylamine). Naunyn-Schmiedeberg’s Arch. Pharmacol., (264): 22 7–228, 1969.Google Scholar
  2. 2.
    Fleckenstein A: Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. (17): 149–166, 1977.PubMedCrossRefGoogle Scholar
  3. 3.
    Bailey JC, Elharrar V, Zipes, DP: Slow-channel depolarization: Mechanism and control of arrhythmias. Annu. Rev. Med. 29:417–426, 1978.PubMedCrossRefGoogle Scholar
  4. 4.
    Luchi RJ, Chahine RA, Raizner AE Coronary artery spasm. Ann. Int. Med. (91): 5441–449, 1979.CrossRefGoogle Scholar
  5. 5.
    Rahwan RG, Piascik MF, Witiak DT: The role of calcium antagonism in the therapeutic action of drugs. Can. J. Physiol. Pharmcol. (57): 443–460, 1979.CrossRefGoogle Scholar
  6. 6.
    Henry PD: Calcium ion antagonists: Mechanisms of action and clinical applications. Pract. Cardiol. (5): 145–156, 1979.Google Scholar
  7. 7.
    Triggle DJ, Swamy VC: Pharmacology of agents that affect calcium. Chest (78): 174–1 79, 1980.Google Scholar
  8. 8.
    Seminar on Calcium Channel Blockers, Part 1. Am. J. Cardiol. 46: 1045–1067, 1980.Google Scholar
  9. 9.
    Seminar on Calcium Channel Blockers, Part 2. Am. J. Cardiol. 47: 15 7–184, 1981.Google Scholar
  10. 10.
    Nayler WG: Calcium antagonists. Eur. Heart J. (1): 225–237, 1980.PubMedCrossRefGoogle Scholar
  11. 11.
    Church J, Zsoter TT: Calcium antgonistic drugs: Mechanism of action. Can. J. Physiol. Pharmacol. (58): 254–264, 1980.PubMedCrossRefGoogle Scholar
  12. 12.
    Berne RM: Cardiac nucleotides in hypoxia: Possible role in regulation of coronary blood flow. Am. J. Physiol. (204): 317–322, 1963.PubMedGoogle Scholar
  13. 13.
    Rubio R, Berne RM: Release of adenosine by the normal myocardium in dog and its relationship to the regulation of coronary resistance. Circ. Res. (25): 407–415, 1969.PubMedCrossRefGoogle Scholar
  14. 14.
    Berne RM: The role of adenosine in the regulation of coronary blood flow. Clrc. Res. (47): 807–813, 1980.CrossRefGoogle Scholar
  15. 15.
    Dutta P, Mustafa SJ: Binding of adenosine to the crude plasma membrane fraction isolated from dog coronary and carotid arteries. J. Pharmacol. Exp. Ther. (214): 496–502, 1980.PubMedGoogle Scholar
  16. 16.
    Mustafa SJ: Cellular and molecular mechanisms of coronary flow regulation by adenosine. Mol. Cell. Biochem. (31): 67–87, 1980.PubMedCrossRefGoogle Scholar
  17. 17.
    Lenke D, Brock N, Zechel HJ: Zur pharmakologie von 1,4-Bis (3-(3,4,5- trimethoxybenzoyloxy)-propyl)-perhydro-1,4-diazepin (Dilazep, INN), einer neuen koronaraktiven substanz. Arzneim.-Forsch. (22):639–651, 1972.Google Scholar
  18. 18.
    Hockerts T, Bogelmann G: Investigations of the cardiac and circulatory action of 2,6-Bis(diethanolamino)-4,8-dipiperidino-pyrimido (5,4-d) pyrimidine. Arzneim.-Forsch. (9): 47–49, 1959.Google Scholar
  19. 19.
    Schaper WKA, Xhonneux R, Jageneau AHM, Janssen PAJ: The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator. J. Pharmac. (152): 265–274, 1966.Google Scholar
  20. 20.
    Sano N, Katsuki S, Kawada M: Enhancement of coronary vasodilator action of adenosine by 1,4-Bis[3(3,4,5-trimenthoxybenzoyloxy)-propyl]- perhydro-1,4-diazepine (Dilazep, INN). Arzneim.-Forsch. 22:1655–1658, 1972.Google Scholar
  21. 21.
    Buyniski JP, Losada M, Bierwagen ME, Gardier RW: Cerebral and coronary vascular effects of a symmetrical N,N’-disubstituted hexahydrodiazepine. J. Pharmacol. Exp. Ther. (181): 522–528, 1972.PubMedGoogle Scholar
  22. 22.
    Katano Y, Takeda K, Otorii T, Horii D, Imai S: Effects of dilazep, dipyridamole and hexobenzine on the heart and coronary circulation. Folia Pharmacol. Jopon. 70:305–314, 1974 (Abs. in English).CrossRefGoogle Scholar
  23. 23.
    Mustafa SJ: Effects of coronary vasodilator drugs on the uptake and release of adenosine in cardiac cells. Biochem. Pharmacol. 28: 2617–2624, 1979.PubMedCrossRefGoogle Scholar
  24. 24.
    Turnheim K, Pittner H, Kolassa N, Kraupp O: Relaxation of coronary artery strips by adenosine and acidosis. Eur. J. Pharmac. (41):217–220, 1977.CrossRefGoogle Scholar
  25. 25.
    Schrader J, Rubio R, Berne RM: Inhibition of slow action potentials of guinea pig atria muscle by adenosine: A possible effect on Ca2+ influx. J. Mol. Cell. Cardiol. (7): 427–433, 1975.PubMedCrossRefGoogle Scholar
  26. 26.
    Fenton RA, Bruttig SP, Rubio R, Berne RM: Effect of adenosine on calcium uptake by intact and cultured vascular smooth muscle. Am. J. Phsyiol. (242):H797–H804, 1982.Google Scholar
  27. 27.
    Griffith SG, Meghji P, Moody CJ, Burnstock G: 8-phenyltheophylline; A potent P1-purinoceptor antagonist. Eur. J. Pharmacol. (75): 61–64, 1981.PubMedCrossRefGoogle Scholar
  28. 28.
    Thyrum PT: Inotropic stimuli and systolic transmembrane calcium flow in depolarized guinea-pig atria. J. Pharmacol. Exp. Ther. 188: 166–179, 1974.PubMedGoogle Scholar
  29. 29.
    Hashimoto K, Takeda K, Katano Y, Nakagawa Y, Tsukada T, Hashimoto T, Schimamoto N, Sakai K, Otorii T, Imai S: Effects of niludipine (Bay a 7168) on the cardiovascular system; with a note on its calcium- antagonistic effects. Arzneim.-Forsch. 29: 1368–1373, 1979.Google Scholar
  30. 30.
    Gross GJ, Diemer MJ, Warltier DC, Hardman HF: Relaxation of potassium-depolarized canine, bovine and porcine large coronary arteries by nitroglycerin, chromonar and two dihydropyridine calcium antagonists. Gen. Pharmac. (12): 199–204, 1981.CrossRefGoogle Scholar
  31. 31.
    Askar AO, Mustafa SJ: Effect of calcium antagonists on the adenosine induced relaxation of bovine coronary arteries. (Abstr.). Fed. Proc. 41 (3): 1529, 1982.Google Scholar
  32. 32.
    Nabata H: Effects of calcium-antagonistic coronary vasodilators on myocardial contractility and membrane potentials. Japan. J. Pharmacol. (27): 239–249, 1977.CrossRefGoogle Scholar
  33. 33.
    Herlihy JT, Bockman EL, Berne RM, Rubio R: Adenosine relaxation of isolated vascular smooth muscle. Am. J. Physiol. (230): 1239–1243, 1976.PubMedGoogle Scholar
  34. 34.
    Foley DH, Amsterdam EA, Mason DT: Interactions of vasoactive effects of adenosine and potassium ion on isolated feline coronary artery smooth muscle. Circ. Res. (44): 207–215, 1979.PubMedCrossRefGoogle Scholar
  35. 35.
    Verhaeghe RH: Action of adenosine and adenine nucleotides on dog’s isolated veins. Am. J. Physiol. (233) H114–H121, 1977.PubMedGoogle Scholar
  36. 36.
    Dutta P, Mustafa SJ, Jones AW: Effect of adenosine on the uptake and efflux of calcium by coronary arteries (Abstr.) Fed. Proc. 39 (3): 530, 1980.Google Scholar
  37. 37.
    Askar AO, Mustafa SJ: Interaction between calcium entry blockers and adenosine (Abstr.) Pharmacologists 25 (3): 244, 1983.Google Scholar
  38. 38.
    Imai S, Takeda K: Effect of vasodilators upon the isolated taenia coli of the guinea pig. J. Pharmacol. Exp. Therap. (156): 557–564, 1967.Google Scholar
  39. 39.
    Evans DS, Sehenden JA: Adenosine receptors mediating cardiac depression. Life Sei. (31): 2425–2432, 1982.CrossRefGoogle Scholar
  40. 40.
    Collis MG: Evidence for an A1-adenosine receptor in the guinea pig atrium. Br. J. Pharmac. (78): 207–212, 1983.CrossRefGoogle Scholar
  41. 41.
    Kucukhuseyin C, Kayaalp SO: Enhancement of the muscle effects of adenosine by lidoflazine and dipyridamole in isolated atria. Arch. Int. Pharmacodyn. (208): 243–250, 1974.PubMedGoogle Scholar
  42. 42.
    Perez JE, Borda L, Schuchleib R, Henry PD: Inotropic and chronotropic effects of vasodilators. J. Pharmacol. Exp. Ther. (221): 609–613, 1982.PubMedGoogle Scholar
  43. 43.
    Camilion de Hurtado MC, Cingolani HE: Interaction between calcium and slow channel blocking drugs on atrial rate. Naunyn-Schmiedeberg’s Arch. Pharmacol. 322:65–71, 1983.CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Y. Nakagawa
  • M. Gudenzi
  • S. Jamal Mustafa

There are no affiliations available

Personalised recommendations